biostudies-literatureUnknown101(5)Boquoi AUniversitätsklinikum Düsseldorf. Anstalt öffentlichen RechtsMyelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after treatment for multiple myeloma (MM). We identified 250 patients with therapy-associated MDS or AML in the Duesseldorf MDS registry. Of those, 50 patients were previously diagnosed with multiple myeloma (mm-MDS/AML). We compared them to patients with de novo MDS (n = 4862) and to patients with MDS following other underlying diseases (tMDS) (n = 200). mm-MDS patients and tMDS patients showed similar karyotypes and degrees of cytopenia. However, mm-MDS patients had significantly higher blast counts and more often belonged to the high-risk group according to the International PAnnals of hematology1031-1038https://www.ebi.ac.uk/biostudies/studies/S-EPMC8993729biostudies-literatureTherapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.PMC8993729Mohring ASavickaite IBoquoi AHildebrandt BGattermann NKobbe GSchroeder TFenk RBanahan SMStrapatsas JHaas RGerming UfalseTherapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after treatment for multiple myeloma (MM). We identified 250 patients with therapy-associated MDS or AML in the Duesseldorf MDS registry. Of those, 50 patients were previously diagnosed with multiple myeloma (mm-MDS/AML). We compared them to patients with de novo MDS (n = 4862) and to patients with MDS following other underlying diseases (tMDS) (n = 200). mm-MDS patients and tMDS patients showed similar karyotypes and degrees of cytopenia. However, mm-MDS patients had significantly higher blast counts and more often belonged to the high-risk group according to the International P2022-01-01T00:00:00Z2022 May2025-04-04T08:24:22.311Z2025-04-04T08:24:22.311ZS-EPMC89937293526286810.1007/s00277-022-04775-1